-
2023-509049-11-00
5
2020-01-01
FIGO stage III ovarian cancer who are eligible for primary cytoreducti
-
2022-502478-18-00
4
2019-12-20
Acute Myeloid Leukemia (AML)
-
2024-514829-36-00
5
2019-12-02
High-risk biochemically-relapsed prostate adenocarcinoma following rad
-
2024-510887-22-00
5
2019-09-30
Mild cognitive impairment due to Alzheimer's disease or mild Alzheimer
-
2023-507886-25-00
4
2019-09-27
Previously untreated and symptomatic patients with histologically prov
-
2023-505810-12-00
5
2019-09-03
Lower limb spasticity
-
2024-516847-23-00
4
2019-08-27
ER-positive and HER2-negative metastatic or locally advanced breast ca
-
2024-514885-38-00
5
2019-07-11
severe forms of mucous membrane pemphigoid
-
2023-504932-16-00
5
2019-06-04
Muscle Invasive Bladder Cancer
-
2023-510357-42-00
5
2019-05-22
hormone receptor (HR)-positive, HER2-negative,
early breast cancer (EB
-
2024-512667-31-00
5
2019-04-23
Main cohort: Patients with unresected Stage I/II, lymph-node negative
-
2022-502832-37-00
5
2019-03-01
Acute myeloid leukemia
-
2024-512585-34-00
4
2019-02-27
Indolent Systemic Mastocytosis (ISM)
-
2022-502937-24-00
5
2019-01-02
Atopic Dermatitis
-
2024-513206-65-00
5
2018-08-10
resected squamous cell carcinoma of head and neck
-
2023-505286-84-00
4
2018-06-25
Pancreatic well differentiated neuroendocrine tumors (NET)
-
2023-509500-15-00
9
2018-05-03
Adult patients with advanced or metastatic solid tumors
-
2023-504820-24-00
5
2018-03-21
Neoadjuvant/Adjuvant treatment for participants with Resectable Stage
-
2024-512470-10-00
11
2018-02-02
End-stage Renal disease
-
2023-509169-19-00
5
2017-07-11
Advanced ALK positive non-small cell lung cancer
-
2024-517489-41-00
5
2017-03-27
High-risk stage III colon cancer
-
2024-513972-16-00
5
2017-01-30
- Resected tumors of sinuses or salivary glands
- Non-operable tumors
-
2024-513078-23-00
4
2016-12-02
breast cancer in young women
-
2024-515846-18-00
7
2016-09-19
Newly diagnosed Diffuse Large B Cell Lymphoma